UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?
Parcel delivery giant UPS (NYSE:UPS) has seen its fair share…
Buy
57
ELTP Quote, Financials, Valuation and Earnings
Last price:
$0.53
Seasonality move
:
-8.34%
Day range:
$0.51 - $0.53
52-week range:
$0.16 - $0.75
Dividend yield:
0%
P/E ratio:
24.57x
P/S ratio:
8.03x
P/B ratio:
15.52x
Volume:
591.6K
Avg. volume:
676.6K
1-year change:
213.25%
Market cap:
$565.5M
Revenue:
$56.6M
EPS (TTM):
-$0.02
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Elite Pharmaceuticals has 655.57% upside to fair value with a price target of -- per share.
ELTP vs. S&P 500
-
Over the past 5 trading days, Elite Pharmaceuticals has overperformed the S&P 500 by 2.68% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Elite Pharmaceuticals does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Elite Pharmaceuticals revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Elite Pharmaceuticals reported revenues of $14.4M.
Earnings Growth
-
Elite Pharmaceuticals earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Elite Pharmaceuticals reported earnings per share of -$0.01.
Enterprise value:
564.6M
EV / Invested capital:
--
Price / LTM sales:
8.03x
EV / EBIT:
401.60x
EV / Revenue:
8.07x
PEG ratio (5yr expected):
0.15x
EV / Free cash flow:
165.28x
Price / Operating cash flow:
164.55x
Enterprise value / EBITDA:
121.29x
Gross Profit (TTM):
$30.9M
Return On Assets:
-21.15%
Net Income Margin (TTM):
-25.7%
Return On Equity:
-36.56%
Return On Invested Capital:
-31.71%
Operating Margin:
7.64%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $33.2M | $47.3M | $70M | $15.5M | $14.4M | |
| Gross Profit | $16.2M | $21.7M | $30.9M | $7M | $6.1M | |
| Operating Income | $4.9M | $7M | $12.2M | $3.5M | $1.1M | |
| EBITDA | $7.7M | -$317.6K | -$14.5M | $377.9K | -$10.1M | |
| Diluted EPS | $0.00 | $0.01 | -$0.02 | -- | -$0.01 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $14.5M | $17.5M | $33.2M | $37.2M | $48M | |
| Total Assets | $28.7M | $31.9M | $52.7M | $74.7M | $90.8M | |
| Current Liabilities | $7.2M | $5.9M | $6.7M | $19.2M | $14.7M | |
| Total Liabilities | $12M | $9.2M | $22.5M | $28.3M | $54.3M | |
| Total Equity | $16.6M | $22.8M | $30.2M | $46.4M | $36.4M | |
| Total Debt | $4.4M | $1.8M | $16M | $7.6M | $7.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2M | -$2.4M | $5.6M | -$2.4M | -$1.1M | |
| Cash From Investing | -$5.5M | -$942.2K | -$2M | -$406K | -- | |
| Cash From Financing | $14.1M | -$8.8M | -$1M | -$37.6K | -$193.1K | |
| Free Cash Flow | -$3.5M | -$3.3M | $3.4M | -$2.8M | -$1.1M | |
ELTP
Sector
Market Cap
$565.5M
$34.7M
Price % of 52-Week High
--
42.33%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.66%
1-Year Price Total Return
213.25%
-41.18%
Beta (5-Year)
0.033
0.653
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.50
200-day SMA
Buy
Level
$0.45
Bollinger Bands (100)
Buy
Level
0.42 - 0.52
Chaikin Money Flow
Sell
Level
-430.9K
20-day SMA
Buy
Level
$0.45
Relative Strength Index (RSI14)
Buy
Level
68.81
ADX Line
Buy
Level
32.54
Williams %R
Neutral
Level
-23.2648
50-day SMA
Buy
Level
$0.44
MACD (12, 26)
Buy
Level
0.04
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Neutral
Level
19.1K
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.9519)
Buy
CA Score
(Annual)
Level (0.8627)
Sell
Beneish M-Score
(Annual)
Level (2.395)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-1.2219)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
Stock Forecast FAQ
In the current month, ELTP has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ELTP average analyst price target in the past 3 months is --.
-
Where Will Elite Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Elite Pharmaceuticals share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Elite Pharmaceuticals?
Analysts are divided on their view about Elite Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Elite Pharmaceuticals is a Sell and believe this share price will drop from its current level to --.
-
What Is Elite Pharmaceuticals's Price Target?
The price target for Elite Pharmaceuticals over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ELTP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Elite Pharmaceuticals is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of ELTP?
You can purchase shares of Elite Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Elite Pharmaceuticals shares.
-
What Is The Elite Pharmaceuticals Share Price Today?
Elite Pharmaceuticals was last trading at $0.53 per share. This represents the most recent stock quote for Elite Pharmaceuticals. Yesterday, Elite Pharmaceuticals closed at $0.53 per share.
-
How To Buy Elite Pharmaceuticals Stock Online?
In order to purchase Elite Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Coinbase Stock Be in 5 Years?
If you’ve been anywhere near the crypto world over the…
How High Will Planet Labs Stock Go in 2025?
Today we dive into Planet Labs (NYSE: PL), the satellite…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 38x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 45x
Sell
33
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Buy
55
SBET alert for May 27
SharpLink Gaming [SBET] is up 429.61% over the past day.
Buy
60
MRUS alert for May 27
Merus NV [MRUS] is down 6.93% over the past day.
Buy
57
RGC alert for May 27
Regencell Bioscience Holdings [RGC] is down 8.85% over the past day.
